SOURCE: IO Circuit

July 16, 2007 06:35 ET

(OTC: CWRL) Gets Accumulate Rating by The Micro-Cap Opportunity

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO Circuit.

LAKE HARMONY, PA--(Marketwire - July 16, 2007) - The Micro-Cap Opportunity, a Los Angeles-based online financial publication that provides market commentary and speculative trading opportunities in micro-cap companies, initiated coverage this morning on shares of online social networking and user-created content and distribution service, CornerWorld Corp. (OTCBB: CWRL) with a rating of 'Accumulate' and a 12-month price target of $5.00. The Micro-Cap Opportunity cites the Company's "category killer" applications, continuing growth in the social networking phenomenon, large premiums offered or paid by Global 2000 media and technology companies to acquire social networking platforms in order to leverage social networking against existing offerings and a large number of Global 2000 companies that have yet to make social networking acquisitions and may need to in order to "keep up" as the basis for the rating.

To read and/or download the full coverage report, please visit The Micro-Cap Opportunity website at

To read the complete release, go to

About The Micro-Cap Opportunity

The Micro-Cap Opportunity is a premier online publication for investors who wish to experience huge profits by investing in up-and-coming publicly traded companies.

The Micro-Cap Opportunity newsletter and email alert service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to catalyst-driven AMEX, NASDAQ, NYSE ARCA, OTCBB and Pink Sheet companies that have the potential of showing increased activity and price action.

Join us at for a complimentary subscription to the most exciting online financial newsletter on the market.

Other active stocks are CMGI, Inc. (NASDAQ: CMGI), Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) and PDL BioPharma, Inc. (NASDAQ: PDLI).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $550.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation do no trading of any kind and send No Faxes or emails.

Contact Information